Identification of Motivators and Barriers Impacting Successful Food Introduction or Reintroduction after Negative Oral Food Challenges

Christina M Ditlof; Roxanne H Hummel; Sam Wong; Carmen H Li; Mara Alexanian-Farr; Slavka O Zahrebelny; Jennifer A Hoang; Lisa Hung; Julia E M Upton; Adelle R Atkinson; Maria Asper; David Hummel; Thomas Eiwegger

doi:10.1016/j.jaip.2023.03.040

Identification of Motivators and Barriers Impacting Successful Food Introduction or Reintroduction after Negative Oral Food Challenges

Christina M Ditlof, Roxanne H Hummel, Sam Wong, Carmen H Li, Mara Alexanian-Farr, Slavka O Zahrebelny, Jennifer A Hoang, Lisa Hung, Julia E M Upton, Adelle R Atkinson, Maria Asper, David Hummel, Thomas Eiwegger

Klinische Abteilung für Kinder- und Jugendheilkunde (Universitätsklinikum St. Pölten)

Publikation: Beitrag in Fachzeitschrift (peer-reviewed) › Artikel in Fachzeitschrift

Originalsprache	Englisch
Seiten (von - bis)	1969-1971.e2
Fachzeitschrift	Journal of Allergy and Clinical Immunology: In Practice
Jahrgang	11
Ausgabenummer	6
Frühes Online-Datum	28 März 2023
DOIs	https://doi.org/10.1016/j.jaip.2023.03.040
Publikationsstatus	Veröffentlicht - Juni 2023

Zugriff auf Dokument

10.1016/j.jaip.2023.03.040

Andere Dateien und Links

Verknüpfung zur Publikation in Scopus

Dieses zitieren

Ditlof, C. M., Hummel, R. H., Wong, S., Li, C. H., Alexanian-Farr, M., Zahrebelny, S. O., Hoang, J. A., Hung, L., Upton, J. E. M., Atkinson, A. R., Asper, M., Hummel, D., & Eiwegger, T. (2023). Identification of Motivators and Barriers Impacting Successful Food Introduction or Reintroduction after Negative Oral Food Challenges. Journal of Allergy and Clinical Immunology: In Practice, 11(6), 1969-1971.e2. https://doi.org/10.1016/j.jaip.2023.03.040

@article{4dba51aa4392484b819df335719b9869,

title = "Identification of Motivators and Barriers Impacting Successful Food Introduction or Reintroduction after Negative Oral Food Challenges",

author = "Ditlof, {Christina M} and Hummel, {Roxanne H} and Sam Wong and Li, {Carmen H} and Mara Alexanian-Farr and Zahrebelny, {Slavka O} and Hoang, {Jennifer A} and Lisa Hung and Upton, {Julia E M} and Atkinson, {Adelle R} and Maria Asper and David Hummel and Thomas Eiwegger",

note = "Funding Information: This work has been supported by unrestricted grants from the Food Allergy and Anaphylaxis Program at the Hospital for Sick Children. Conflicts of interest: J. E. M. Upton reports grants/research support from DBV Technologies, Regeneron, CIHR, ALK-Abell{\'o}, and the SickKids Food Allergy and Anaphylaxis Program; served on the advisory board for Pfizer, Kaleo, Bausch Health, and Food Allergy Canada; received an in-kind drug donation from Novartis; and other services for Astra-Zeneca, all outside the current work. T. Elwegger reports to act as a local principal investigator for company-sponsored trials by DBV Therapeutics, and Greer Stallergens; as a subinvestigator for Regeneron and ALK-Abell{\'o}; is co-investigator or scientific lead in 3 investigator-initiated oral immunotherapy trials supported by the SickKids Food Allergy and Anaphylaxis Program; serves as an associate editor for Allergy; his laboratory received unconditional/in-kind contributions from Macro Array Diagnostics and an unrestricted grant from ALK-Abell{\'o}; holds advisory board roles for ALK-Abell{\'o}, VAMED, Nutricia/Danone, and Aimmune; and reports lecture fees from Novartis, ThermoFisher, Nutricia/Danone, Aimmune, and ALK-Abell{\'o}. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: This work has been supported by unrestricted grants from the Food Allergy and Anaphylaxis Program at the Hospital for Sick Children. Funding Information: Conflicts of interest: J. E. M. Upton reports grants/research support from DBV Technologies, Regeneron, CIHR, ALK-Abell{\'o}, and the SickKids Food Allergy and Anaphylaxis Program; served on the advisory board for Pfizer, Kaleo, Bausch Health, and Food Allergy Canada; received an in-kind drug donation from Novartis; and other services for Astra-Zeneca, all outside the current work. T. Elwegger reports to act as a local principal investigator for company-sponsored trials by DBV Therapeutics, and Greer Stallergens; as a subinvestigator for Regeneron and ALK-Abell{\'o}; is co-investigator or scientific lead in 3 investigator-initiated oral immunotherapy trials supported by the SickKids Food Allergy and Anaphylaxis Program; serves as an associate editor for Allergy; his laboratory received unconditional/in-kind contributions from Macro Array Diagnostics and an unrestricted grant from ALK-Abell{\'o}; holds advisory board roles for ALK-Abell{\'o}, VAMED, Nutricia/Danone, and Aimmune; and reports lecture fees from Novartis, ThermoFisher, Nutricia/Danone, Aimmune, and ALK-Abell{\'o}. The rest of the authors declare that they have no relevant conflicts of interest. ",

year = "2023",

month = jun,

doi = "10.1016/j.jaip.2023.03.040",

language = "English",

volume = "11",

pages = "1969--1971.e2",

journal = "Journal of Allergy and Clinical Immunology: In Practice",

issn = "2213-2198",

publisher = "American Academy of Allergy, Asthma and Immunology",

number = "6",

}

Ditlof, CM, Hummel, RH, Wong, S, Li, CH, Alexanian-Farr, M, Zahrebelny, SO, Hoang, JA, Hung, L, Upton, JEM, Atkinson, AR, Asper, M, Hummel, D & Eiwegger, T 2023, 'Identification of Motivators and Barriers Impacting Successful Food Introduction or Reintroduction after Negative Oral Food Challenges', Journal of Allergy and Clinical Immunology: In Practice, Jg. 11, Nr. 6, S. 1969-1971.e2. https://doi.org/10.1016/j.jaip.2023.03.040

Identification of Motivators and Barriers Impacting Successful Food Introduction or Reintroduction after Negative Oral Food Challenges. / Ditlof, Christina M; Hummel, Roxanne H; Wong, Sam et al.
in: Journal of Allergy and Clinical Immunology: In Practice, Jahrgang 11, Nr. 6, 06.2023, S. 1969-1971.e2.

Publikation: Beitrag in Fachzeitschrift (peer-reviewed) › Artikel in Fachzeitschrift

TY - JOUR

T1 - Identification of Motivators and Barriers Impacting Successful Food Introduction or Reintroduction after Negative Oral Food Challenges

AU - Ditlof, Christina M

AU - Hummel, Roxanne H

AU - Wong, Sam

AU - Li, Carmen H

AU - Alexanian-Farr, Mara

AU - Zahrebelny, Slavka O

AU - Hoang, Jennifer A

AU - Hung, Lisa

AU - Upton, Julia E M

AU - Atkinson, Adelle R

AU - Asper, Maria

AU - Hummel, David

AU - Eiwegger, Thomas

N1 - Funding Information: This work has been supported by unrestricted grants from the Food Allergy and Anaphylaxis Program at the Hospital for Sick Children. Conflicts of interest: J. E. M. Upton reports grants/research support from DBV Technologies, Regeneron, CIHR, ALK-Abelló, and the SickKids Food Allergy and Anaphylaxis Program; served on the advisory board for Pfizer, Kaleo, Bausch Health, and Food Allergy Canada; received an in-kind drug donation from Novartis; and other services for Astra-Zeneca, all outside the current work. T. Elwegger reports to act as a local principal investigator for company-sponsored trials by DBV Therapeutics, and Greer Stallergens; as a subinvestigator for Regeneron and ALK-Abelló; is co-investigator or scientific lead in 3 investigator-initiated oral immunotherapy trials supported by the SickKids Food Allergy and Anaphylaxis Program; serves as an associate editor for Allergy; his laboratory received unconditional/in-kind contributions from Macro Array Diagnostics and an unrestricted grant from ALK-Abelló; holds advisory board roles for ALK-Abelló, VAMED, Nutricia/Danone, and Aimmune; and reports lecture fees from Novartis, ThermoFisher, Nutricia/Danone, Aimmune, and ALK-Abelló. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: This work has been supported by unrestricted grants from the Food Allergy and Anaphylaxis Program at the Hospital for Sick Children. Funding Information: Conflicts of interest: J. E. M. Upton reports grants/research support from DBV Technologies, Regeneron, CIHR, ALK-Abelló, and the SickKids Food Allergy and Anaphylaxis Program; served on the advisory board for Pfizer, Kaleo, Bausch Health, and Food Allergy Canada; received an in-kind drug donation from Novartis; and other services for Astra-Zeneca, all outside the current work. T. Elwegger reports to act as a local principal investigator for company-sponsored trials by DBV Therapeutics, and Greer Stallergens; as a subinvestigator for Regeneron and ALK-Abelló; is co-investigator or scientific lead in 3 investigator-initiated oral immunotherapy trials supported by the SickKids Food Allergy and Anaphylaxis Program; serves as an associate editor for Allergy; his laboratory received unconditional/in-kind contributions from Macro Array Diagnostics and an unrestricted grant from ALK-Abelló; holds advisory board roles for ALK-Abelló, VAMED, Nutricia/Danone, and Aimmune; and reports lecture fees from Novartis, ThermoFisher, Nutricia/Danone, Aimmune, and ALK-Abelló. The rest of the authors declare that they have no relevant conflicts of interest.

PY - 2023/6

Y1 - 2023/6

UR - http://www.scopus.com/inward/record.url?scp=85152692160&partnerID=8YFLogxK

U2 - 10.1016/j.jaip.2023.03.040

DO - 10.1016/j.jaip.2023.03.040

M3 - Journal article

C2 - 36997121

SN - 2213-2198

VL - 11

SP - 1969-1971.e2

JO - Journal of Allergy and Clinical Immunology: In Practice

JF - Journal of Allergy and Clinical Immunology: In Practice

IS - 6

ER -